Navigation Links
New Hope for Liver Diseases
Date:5/23/2008

Scientists generate liver cells from embryonic stem cells, find clues to predict response to therapy

FRIDAY, May 23 (HealthDay News) -- Human liver cells have been generated from embryonic stem cells using a new model, hopefully opening the door to help scientists screen for harmful side effects of new drugs before they are used in patients.

That was one of several reports on advances against liver diseases that were presented this week at Digestive Disease Week 2008 in San Diego.

Other presentations involved ways to predict which patients with hepatitis C might benefit from long-term antibiotic therapy and information about how monitoring the body's viral load in hepatitis B patients may help predict liver cancer.

Scientists from the University of Edinburgh, Scotland, reported they had efficiently generated human liver cells from embryonic stem cells without the problems that have plagued scientists in the past. The new model is unique, said Dr. David Hay, a senior fellow at the university's MRC Centre for Regenerative Medicine, who spoke at a press conference Tuesday.

His team developed a model that allows them to focus on key enzymes which are crucial in drug metabolism. Other clinical applications, he said, include the fact that the liver cells generated in vitro could be used in bioartificial devices, helping maintain normal function when the liver fails.

Down the road, said another investigator, Dr. Philip Newsome, the hope is that the cells could be used in liver transplantation.

The advance was praised by the press conference moderator, Dr. John M. Vierling, chief of hepatology at Baylor College of Medicine, in Houston.

The team produced "highly differentiated cells that maintain function," Vierling said, a feat that has thus far proved elusive to others working on the effort. "It is an extraordinarily rich advance to be exploited in many ways," he added.


'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Sea Buckthorn Leaves May Hold Benefit for the Liver
2. Arctic explorer delivers unique snow-depth data for CryoSat
3. Miracle leaves that may help protect against liver damage
4. The Childrens Hospital of Philadelphia Opens the Worlds First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus
5. What roles does TSP-1 play in liver fibrogenesis?
6. Is extra-corporal liver support with prometheus safe in patients with end-stage liver disease?
7. Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM)
8. Risk threshold of daily alcohol intake and drinking duration in liver injury?
9. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
10. AmeriCares Delivers Life-Saving Aid to Myanmar
11. Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Hope for Liver Diseases
(Date:5/21/2013)... (PRWEB) May 21, 2013 MedMar Healing ... drive to benefit Second Harvest Food Bank. Twenty-eight businesses, including ... participate in the food drive. The goal is to raise ... the economic problems facing their families in recent years. ... community and help those in need,” explains Douglas Chloupek of ...
(Date:5/21/2013)... recently published in the New England Journal of ... the University of Colorado School of Medicine finds that ... be used to identify individuals at risk for this ... common variant of the gene for mucin-5B, a protein ... the bronchial tubes. While this variant of the MUC5B ...
(Date:5/21/2013)... Research into genetic features of pulmonary fibrosis by ... of Medicine may lead to improved treatment of this ... by JAMA . , The study found that ... cases of pulmonary fibrosis, a chronic progressive disease with ... of the study, researchers may want to consider including ...
(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... robot lawsuit is nearing its conclusion in Washington ... Bloomberg.com, during closing statements yesterday, an attorney for the ... the company wanted to tie sales and services for ... the training to keep control of surgeons, to keep ...
Breaking Medicine News(10 mins):Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4
... ... PhD, JD, is Keynote Speaker on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- ... Drug Policy Alliance advocating for drug reform in the United States as keynote speaker former ...
... acoustic neuromas , FRIDAY, Sept. 11 (HealthDay News) -- Last ... or the sound of a dog barking. She was 22. ... type 2 (NF2), a condition characterized by tumors in the ... cranial nerve in one ear. , The result: increasing hearing ...
... affects insulin resistance, study finds, , FRIDAY, Sept. 11 (HealthDay ... insight into type 2 diabetes, potentially leading to better treatment ... appears to be linked to diabetes, affects how the body ... published Sept. 6 in Nature Genetics . , "Most ...
... Duane Reade Holdings Inc., the largest drug store in metropolitan New ... 2009 Komen New York City Race For The Cure, the Company, ... raised $330,000 to increase awareness of breast cancer and to assist ... year that Duane Reade has proudly sponsored this momentous event, with ...
... , , MADISON, N.J. and ... (FDA) today cleared the OVA1(TM) Test, the first blood test that, ... at risk for a malignant pelvic mass. OVA1 is the first ... with high sensitivity prior to biopsy or exploratory surgery, even if ...
... , , , ... Gardasil, declined by a third this year, and three years after ... women remain unvaccinated -- despite millions spent on advertising and lobbying ... , , Michelle Steward, assistant professor of marketing ...
Cached Medicine News:Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 2Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 4Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 5Health News:HPV Vaccine Study Shows Why Few Women Getting Shots 2
(Date:5/21/2013)... , May 21, 2013   Accuray Incorporated ... the publication of study results involving hundreds of ... Radiosurgery System, the most widely used form of ... followed 304 patients for a median of 5 ... found that 97 percent of patients with low-risk ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: